Advanced protein glycation in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 2, 2012, Pages 172-179

  Damasiewicz Bodzek, A ^a   Wielkoszynski T ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PSORIASIS; REMISSION;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROTEINS; PSORIASIS;

EID: 84856322779     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04024.x     Document Type: Article

References (64)

1. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
2. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741. (Pubitemid 44547793)
3. Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9. (Pubitemid 44908334)
4. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509. (Pubitemid 351373394)
5. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2007; 298: 321-328.
6. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276. (Pubitemid 46095954)
7. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589. (Pubitemid 351541054)
8. Shapiro J, Cohen A, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634. (Pubitemid 46400186)
9. Singh R, Barden A, Mori T, Beilin L,. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. (Pubitemid 32156196)
10. Tsukahara H, Sekine K, Uchiyama M, et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res 2003; 54: 419-424. (Pubitemid 37013207)
11. ε-(carboxyethyl)- lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50: 1222-1228. (Pubitemid 38824231)
12. Urlich P, Cerami A,. Protein glycation, diabetes and aging. Recent Prog Horm Res 2001; 56: 1-22.
13. Szymańska U, Boratyński J,. Glikacja białek-aspekty kliniczne i chemiczne. Post Med Dośw 1999; 53: 689-703.
14. Miyata T, Ueda Y, Saito A, Kurokawa K,. 'Carbonyl stress' and dialysis-related amyloidosis. Nephrol Dial Transplant 2000; 15: 25-28.
15. Schmidt AM, Yan SD, Wautier J-L, Stern D,. Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497. (Pubitemid 29138585)
16. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: Animal model and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004; 24: 1342-1349. (Pubitemid 39050425)
17. Wautier JL, Guillausseau PJ,. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab (Paris) 2001; 27: 535-542. (Pubitemid 33051702)
18. Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532. (Pubitemid 28397070)
19. Virella G, Thorpe SR, Alderson NL, et al. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003; 44: 487-493. (Pubitemid 37279696)
20. Glorieux G, Helling R, Henle T, et al. In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004; 66: 1873-1880. (Pubitemid 41094311)
21. ε-(carboxymethyl)-lysine, an advanced glycation end product of the Maillard reaction. Diabetes 1999; 48: 1842-1849. (Pubitemid 29415206)
22. Zilin S, Naifeng L, Bicheng L, Jiping W,. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta 2001; 313: 69-75. (Pubitemid 33016693)
23. Goycheva P, Gadjeva V, Popov B,. Oxidative stress and its complications in diabetes mellitus. Trakia J Sci 2006; 4: 1-8.
24. Monnier VM, Mustata GT, Biemel KL, et al. Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: an update on 'a puzzle nearing resolution'. Rejuvenation res 2006; 9: 264-273.
25. Lapolla A, Fedele D, Traldi P,. Glyco-oxidation in diabetes and related diseases. Clin Chim Acta 2005; 357: 236-250. (Pubitemid 40884605)
26. Yan SF, Ramasamy R, Naka Y, Schmidt AM,. Glycation, inflammation and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169. (Pubitemid 37543056)
27. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM,. Pathogenesis of diabetic nephropathy: a radical approach. Nephrol Dial Transplant 1997; 12: 664-668. (Pubitemid 27170417)
28. Yamagishi S, Nakamura K, Imaizumi T,. Advanced glycation end products (AGEs) and diabetic vascular complication. Curr Diabetes Rev 2005; 1: 93-106.
29. Sakata N, Imanaga Y, Meng J, et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998; 141: 61-75. (Pubitemid 28539417)
30. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-667.
31. Wada T, Miyata T, Kurokawa K,. Implication of carbonyl stress in long-term uraemic complications. Nephrol Dial Transplant 1999; 14: 79-81. (Pubitemid 29041849)
32. Kalousova M, Sulkova S, Fialova L, et al. Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2577-2581. (Pubitemid 37483791)
33. Miyata T, Maeda K, Kurokawa K, Strihou Y,. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997; 12: 255-258. (Pubitemid 27090974)
34. Zoccali C, Mallamaci F, Tripepi G,. AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. Nephrol Dial Transplant 2000; 15: 7-11.
35. Munch G, Thome J, Foley P, et al. Advanced glycation end-products in aging and Alzheimer's disease. Brain Res Rev 1997; 23: 134-143. (Pubitemid 27090752)
36. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 1994; 91: 5710-5714. (Pubitemid 24174398)
37. ε- (carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003; 24: 333-338. (Pubitemid 36005413)
38. Ohnuki Y, Nagano R, Takizawa S, et al. Advanced glycation end products in patients with cerebral infarction. J Immunol 2008; 181: 1499-1506.
39. ε- (carboxymethyl)-lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006; 39: 39-45. (Pubitemid 43005268)
40. Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys res Comm 1998; 244: 45-49. (Pubitemid 28419898)
41. ε-(carboxymethyl)-lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468. (Pubitemid 27414803)
42. Masaki H, Okano Y, Sakurai H,. Generation of oxygen species from AGE during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damage. Biochim Biophys Acta 1999; 1428: 45-56. (Pubitemid 29299245)
43. ε-(carboxymethyl)-lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol 1997; 108: 798-802.
44. Offidani AM, Ferreti G, Taus M, et al. Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venerol (Stockh 1994; 186: 38-40. (Pubitemid 24208148)
45. Orem A, Cimsit G, Deger O,. The significance of autoantibodies against oxidatively modified low-density lipoproteins (LDL) in patients with psoriasis. Clin Chim Acta 1999; 284: 81-88. (Pubitemid 29324867)
46. Wielkoszyński T, Świȩtochowska E, Hadas E, et al. Stȩżenie przeciwciał przeciw ox-LDL w surowicy krwi pacjentõw z łuszczyca̧ zwykła̧- doniesienie wstȩpne. Czyn Ryz 2002; 37: 65.
47. Relhan V, Gupta SK, Dayal S, et al. Blood thiols and malondialdehyde levels in psoriasis. J Dermatol 2002; 29: 399-403. (Pubitemid 34857572)
48. Briganti S, Picardo M,. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003; 17: 663-669. (Pubitemid 37428088)
49. Trouba KJ, Hamadeh HK, Amin RP, Germolec DR,. Oxidative stress and its role in skin disease. Antioxid Redox Signal 2002; 4: 665-673. (Pubitemid 35001451)
50. Dimon-Gadal S, Gerbaud P, Therond P, et al. Increased oxidative damage to fibroblasts in skin with and without lesions in psoriasis. J Invest Dermatol 2000; 114: 984-989. (Pubitemid 30252721)
51. Shilov VN, Sergienko VI,. Oxidative stress in keratinocytes as an etiopathogenetic factor of psoriasis. Bull Exp Biol Med 2000; 129: 309-313.
52. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928. (Pubitemid 38903524)
53. Kokcami I, Naziroglu M,. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta 1999; 289: 23-34.
54. Yildrim M, Inaloz HS, Baysal V, Delibas N,. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 34-36. (Pubitemid 36163651)
55. Lohwasser C, Neureiter D, Weigle B, et al. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. Intern Med 2009; 48: 587-591.
56. Vytášek R, Àedová L, Vilím V,. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskeletal Disorders 2010; 11: 83-93.
57. Turk Y, Ljubic S, Turk N, Benko B,. Detection of autoantibodies against advanced glycation end-products and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 2001; 303: 105-115. (Pubitemid 32121812)
58. Wielkoszyński T, Damasiewicz-Bodzek A,. Stȩżenie przeciwciał przeciw końcowym produktom glikacji białek (anty-AGE) w surowicy pacjentõw z łuszczyca̧- doniesienie wstȩpne. Now Lek 2005; 74: 9-13.
59. Wells-Knecht KJ, Zyzak DV, Litchfield JE, et al. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995; 34: 3702-3709.
60. ε- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894. (Pubitemid 17204276)
61. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950. (Pubitemid 34175462)
62. Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP,. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006; 24: 587-593. (Pubitemid 44911257)
63. Kageyama Y, Takahashi M, Nagafusa T, et al. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008; 28: 245-251. (Pubitemid 350265468)
64. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80. (Pubitemid 351385258)